Risks of recurrence of posttransplant lymphoproliferative disease, Hodgkin’s disease or Kaposi’s sarcoma after retransplantation
Lymphomas and lymphoproliferations comprise 24% of posttransplant malignancies and Kaposi’s sarcoma (KS) 6%, if non-melanoma skin cancers and in situ carcinomas of the uterine cervix are excluded, as they are from most studies of patterns of malignancy . A gratifying feature is that following treatment 41% of lymphomas and 36% of KS undergo complete remission. In some patients a complication of such therapy is loss of the allograft, which may necessitate retransplantation. A question that arises is whether retransplan-tation, with reinstitution of full dose immunosuppressive therapy will precipitate recurrence of the neoplasm. The current study examined the data accumulated by the Cincinnati Transplant Tumor Registry (CTTR) from the fall of 1968 till May 1997 to address this question.
KeywordsAutologous Bone Marrow Transplantation Smooth Muscle Tumor Kidney Allograft Renal Allograft Recipient Liver Allograft
Unable to display preview. Download preview PDF.
- 1.Penn I. Epidemiology of cancer in transplant patients. In: Touraine JL, Traeger J, Betuel H, Dubernard JM, Revillard JP, Dupuy C (eds.), Cancer in Transplantation, Prevention and Treatment. Dordrecht: Kluwer Academic Publishers, 1996: 3–15.Google Scholar
- 5.Hickey DP, Nalesnik MA, Vivas CA et al. Renal retransplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease. Clin. Transplant. 1990; 4: 187–190.Google Scholar
- 8.Penn I. Immunosuppression-a contributory factor in lymphoma formation. Clin. Transplant. 1992; 6: 214–219.Google Scholar